BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24673480)

  • 1. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
    Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
    Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
    Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
    Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol].
    Tepliakov AT; Shilov SN; Berezikova EN; Torim IuIu; Efremov AV; Safronov ID; Maianskaia SD; Popova AA; Voronina EN; Karpov RS
    Ter Arkh; 2010; 82(12):22-8. PubMed ID: 21516734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
    Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
    Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and heart failure: a convergence with carvedilol.
    Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
    Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
    Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M;
    J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
    Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
    Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
    Aurich-Barrera B; Wilton LV; Shakir SA
    Drug Saf; 2009; 32(1):43-54. PubMed ID: 19132804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant.
    Iwata A; Miura S; Nishikawa H; Kawamura A; Matsuo Y; Sako H; Kumagai K; Matsuo K; Saku K
    J Cardiol; 2006 Jan; 47(1):1-7. PubMed ID: 16475467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
    Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
    Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
    Franciosa JA; Massie BM; Lukas MA; Nelson JJ; Lottes S; Abraham WT; Fowler M; Gilbert EM; Greenberg B;
    Am Heart J; 2004 Oct; 148(4):718-26. PubMed ID: 15459606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.